Rituximab
WHERE : National Institute of Neurologicial Disorders and Stroke
WHAT: Double Blind Combination of Rituximab by IntraVenous and IntraThecal Injection Versus Placebo
in Patients with Low-Inflammatory Secondary Progressive Multiple Sclerosis.
ONLY 66 PEOPLE FOR STUDY AND I DECLINED. LETS POST ALL INFORMATION HERE ON THIS STUDY.
WHAT: Double Blind Combination of Rituximab by IntraVenous and IntraThecal Injection Versus Placebo
in Patients with Low-Inflammatory Secondary Progressive Multiple Sclerosis.
ONLY 66 PEOPLE FOR STUDY AND I DECLINED. LETS POST ALL INFORMATION HERE ON THIS STUDY.